|
MBIO | Mustang Bio, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 1.03 |
| Leverage | 49.53% |
| Market Cap | $ 9.5m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -2.3m |
| Margin | -528.11% |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, is focused on translating medical advances in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Worcester, Massachusetts.